Intellia Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:NTLA) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -49.91 M-225.03 M-333.29 M-394.09 M-348.88 M-394.74 M -363.15 M Cash from investing activities -214.49 M-550.78 M160.31 M-31.35 M125.57 M228.03 M 200.01 M Cash from financing activities 371.78 M736.69 M582.96 M130.32 M185.75 M131.49 M 165.06 M Free cash flow -49.91 M-225.03 M-333.29 M-394.09 M-348.88 M-394.74 M -363.15 M

News

Intellia Therapeutics: An Overvalued Biotech With Little To No Commercial Potential (NTLA)

Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable (PRME)

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears

Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?

The Disinflation Trade Has A New Address: Genomics

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem?

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

Intellia Therapeutics Stock: Steady Progress, Historic Commercial Approval (NASDAQ:NTLA)

ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?